Format
Sort by

Send to

Choose Destination

Search results

Items: 15

1.

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group.

N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8.

2.

Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp.

Pariser DM, Houlihan A, Ferdon MB, Berg JE; PDT-AK Investigational Group.

Dermatol Surg. 2016 Mar;42(3):296-304. doi: 10.1097/DSS.0000000000000630.

PMID:
26863596
3.

Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.

Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, Gratton D, Kunynetz RA, Poulin Y, Rosoph LA, Stingl G, Bauer WM, Salter JM, Falk TM, Blödorn-Schlicht NA, Hueber W, Sommer U, Schumacher MM, Peters T, Kriehuber E, Lee DM, Wieczorek GA, Kolbinger F, Bleul CC.

Exp Dermatol. 2015 Jul;24(7):529-35. doi: 10.1111/exd.12710. Epub 2015 May 8.

4.

Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.

Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, Marciniak SJ Jr, Wasfi Y, Wang Y, Szapary P, Krueger JG.

J Allergy Clin Immunol. 2014 Apr;133(4):1032-40. doi: 10.1016/j.jaci.2014.01.025.

5.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB; PSUMMIT 2 Study Group.

Ann Rheum Dis. 2014 Jun;73(6):990-9. doi: 10.1136/annrheumdis-2013-204655. Epub 2014 Jan 30.

6.

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.

Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, Schafer PH, Krueger JG.

J Drugs Dermatol. 2013 Aug;12(8):888-97.

PMID:
23986162
7.

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; PSUMMIT 1 Study Group.

Lancet. 2013 Aug 31;382(9894):780-9. doi: 10.1016/S0140-6736(13)60594-2. Epub 2013 Jun 13.

PMID:
23769296
8.

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM.

Lancet. 2012 Aug 25;380(9843):738-46. doi: 10.1016/S0140-6736(12)60642-4. Epub 2012 Jun 29.

PMID:
22748702
9.

Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study.

Szeimies RM, Matheson RT, Davis SA, Bhatia AC, Frambach Y, Klövekorn W, Fesq H, Berking C, Reifenberger J, Thaçi D.

Dermatol Surg. 2009 Apr;35(4):586-92. doi: 10.1111/j.1524-4725.2009.01096.x. Epub 2009 Mar 3.

PMID:
19309347
10.

Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents.

Kimball AB, Gold MH, Zib B, Davis MW; Clobetasol Propionate Emulsion Formulation Foam Phase III Clinical Study Group.

J Am Acad Dermatol. 2008 Sep;59(3):448-54, 454.e1. doi: 10.1016/j.jaad.2008.04.020. Epub 2008 Jun 9.

PMID:
18539358
11.

Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial.

Gollnick H, Kaufmann R, Stough D, Heikkila H, Andriano K, Grinienko A, Jimenez P; Pimecrolimus Cream 1% in (adult) Eczema: Prevention of Progression Multicentre Investigator Study Group.

Br J Dermatol. 2008 May;158(5):1083-93. doi: 10.1111/j.1365-2133.2008.08484.x. Epub 2008 Mar 13.

PMID:
18341665
12.

A randomized trial of etanercept as monotherapy for psoriasis.

Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R.

Arch Dermatol. 2003 Dec;139(12):1627-32; discussion 1632.

PMID:
14676082
13.

Etanercept as monotherapy in patients with psoriasis.

Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB; Etanercept Psoriasis Study Group.

N Engl J Med. 2003 Nov 20;349(21):2014-22.

15.

Absorption and biotransfomation of cholecalciferol in drug-induced osteomalacia.

Matheson RT, Herbst JJ, Jubiz W, Freston JW, Tolman KG.

J Clin Pharmacol. 1976 Aug-Sep;16(8-9):426-32.

PMID:
184119
Items per page

Supplemental Content

Loading ...
Write to the Help Desk